Procyon BioPharma Inc. Shareholders Approve Merger Via Acquisition With Cellpep S.A.

Published: Feb 24, 2006

MONTREAL--(BUSINESS WIRE)--Feb. 24, 2006--Procyon Biopharma Inc. (TSX:PBP), a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced that at its Special Meeting of Shareholders held today, shareholders of Procyon approved the acquisition of Cellpep S.A. and the concurrent $18.1 million private placement of special warrants and units. The name change of Procyon Biopharma Inc. to Ambrilia Biopharma Inc. and the future share consolidation were also approved by Procyon' shareholders.

Back to news